Targeted intracellular delivery of antiviral agents
Assignee2-BBB Medicines B.V.
InventorPieter Jaap GAILLARD
Life of this patent
Estimating the term…
Loading patent…
Assignee2-BBB Medicines B.V.
InventorPieter Jaap GAILLARD
Estimating the term…
The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of antiviral compounds to intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to internalizing uptake receptors present on these cells, tissues and organs. Thereto, the antiviral compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to ligands that facilitate the specific binding to and internalization by these receptors.
A method for delivering a drug across the blood-central nervous system (CNS) barrier, comprising administering to a subject in need thereof an effective amount of a drug-encapsulating nanocontainer that comprises a glutathione receptor (GR)-binding conjugate characterized by a lipid-polyethylene glycol linked to a thiol group of a GR ligand, such that the drug
A method for delivering a drug across the blood-CNS barrier, comprising administering to a subject in need thereof an effective dose of a drug-encapsulating nanocontainer that comprises a glutathione receptor-binding conjugate produced by reacting
Dependencies are inferred from the claim text.